Yarrow Bioscience, Inc. Common Stock
YARW
42 hedge funds and large institutions have $161M invested in Yarrow Bioscience, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 9 closing their positions.
650% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 2
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
39% more capital invested
Capital invested by funds: $116M → $161M (+$44.7M)
20% more funds holding
Funds holding: 35 → 42 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.2M |
| 2 |
First Manhattan
New York
|
+$7.87M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.12M |
| 4 |
O
OrbiMed
New York
|
+$4.04M |
| 5 |
JP Morgan Chase
New York
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.08M |
| 3 |
Millennium Management
New York
|
-$1.74M |
| 4 |
D.E. Shaw & Co
New York
|
-$231K |
| 5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$200K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
51
Prelude Capital Management
New York
| $1K | -$30.9K | -1 | Closed |
|
52
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
PA
53
Perceptive Advisors
New York
| – | -$10.1M | -345 | Closed |
|
|
54
Fidelity Investments
Boston,
Massachusetts
| – | -$9.08M | -311 | Closed |
|
|
55
Millennium Management
New York
| – | -$1.74M | -59 | Closed |
|
|
56
D.E. Shaw & Co
New York
| – | -$231K | -8 | Closed |
|
|
OAM
57
Oxford Asset Management
Oxford,
United Kingdom
| – | -$131K | -5 | Closed |
|
58
Citadel Advisors
Miami,
Florida
| – | -$130K | -4 | Closed |
|
59
Balyasny Asset Management
Chicago,
Illinois
| – | -$96K | -3 | Closed |
|
|
CWM
60
Cornerstone Wealth Management
St. Peters,
Missouri
| – | -$200K | – | – |
|
61
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | – | – |
|
|
PIA
62
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$1K | – | – |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$8K | – | – |
|
64
UBS Group
Zurich,
Switzerland
| – | -$7K | – | – |
|
YARW Hedge Fund Activity: Q3 2018 in Review
42 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2018, worth a combined $161M — up 39% from $116M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new YARW positions and 9 closed out — a net gain of 7 holders — while 15 added to existing stakes and 2 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $11.2M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.1M sold.
- 42 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2018, up from 35 in Q2 2018.
- Funds reported $161M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2018, up 39% quarter-over-quarter.
- 16 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2018 and 9 closed out, a net change of +7 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2018 was Great Point Partners, an estimated $11.2M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2018 was Perceptive Advisors, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2018.